Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD
In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies. Chapters:00:35 - Guest Introduction01:10 - SELECT Results Overview04:25 - Next Steps for Research07:15 - Mechanism of Action for CV Benefit09:00 - FLOW Trial Implications11:25 - Impact on Access15:00 - Future of Incretin Therapies21:45 - Predicting the Next 5-10 Years for Semaglutide
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.